Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has just gotten the green light from the U.S. government to sell a new medicine called Verapamil Hydrochloride Extended-Release Tablets. This medicine is used to treat high blood pressure. High blood pressure increases the risk of serious health problems, such as heart attacks and strokes.

Key Points

• Zydus secured USFDA approval for Verapamil Hydrochloride tablets.
• The tablets treat high blood pressure effectively and safely.
• These tablets lower stroke and heart attack risks.
• Production will occur in Baddi, Himachal Pradesh, India.
• Annual U.S. sales are currently at $24.5 million.
• Market data (IQVIA) shows strong current sales potential.

These tablets slowly release verapamil, which helps keep blood pressure steady. The company makes these tablets at their factory in Baddi, India. This means more people in the United States can access this important medicine.

Zydus Lifesciences reported that the Verapamil tablets had sales of $24.5 million in the United States during the period of September 2025. This figure was compiled by IQVIA, a company that tracks sales of medicines.

This approval is a positive development for Zydus Lifesciences and their efforts to provide effective treatments for cardiovascular health. It demonstrates a continued commitment to improving patient outcomes.

“This approval represents a crucial step in delivering life-saving medication to those in need.”